Defective Breast Mesh, Acellular Dermal Matrix, and Bioabsorbable Scaffold Injury Attorneys in New York: The Definitive Guide for Survivors and Families
The journey through breast reconstruction or augmentation is often one of restoration, hope, and reclaiming one’s sense of self. For many women in New York, particularly those who have triumphed over a breast cancer diagnosis at world-class institutions like Memorial Sloan Kettering Cancer Center, NYU Langone, or New York-Presbyterian, the surgical plan was supposed to be the final step toward healing. However, for a growing number of patients across New York’s five boroughs and surrounding suburbs, that promise has been replaced by a nightmare of chronic pain, severe infection, and a terrifying new diagnosis: medical device-induced cancer.
At The Manginello Law Firm, PLLC, operating under our consumer brand Attorney911, we represent women who were never told the truth about the materials implanted in their bodies. Whether you received an acellular dermal matrix (ADM), a bioabsorbable scaffold like GalaFLEX, or a textured implant now linked to rare lymphomas, we understand the medical, emotional, and legal complexities of your situation. We know that when a medical device fails, it isn’t just a “complication”—it is a violation of the trust you placed in the healthcare system and the manufacturers who claimed their products were safe.
If you are currently navigating the physical and psychological toll of a failed reconstruction or a device-related injury in New York, you are not alone. Our firm, led by Ralph Manginello with nearly three decades of trial experience, and supported by the bilingual advocacy of Lupe Peña, is here to provide the sophisticated, technical, and compassionate representation you deserve. We invite you to call us at 1-888-ATTY-911 for a confidential, no-cost consultation to discuss what happened to you and how we can pursue justice together.
Why Experience Matters in New York Complex Device Litigation
New York is a global hub for medical innovation, but it is also a landscape where complex legal doctrines like the “learned intermediary” and the “discovery rule” can make or break a case. Representing a woman injured by a defective medical device requires more than just general personal injury knowledge; it requires a deep command of FDA regulatory pathways, materials science, and federal preemption law.
Ralph P. Manginello has been licensed by the State Bar of Texas (Bar Card No. 24007597) since 1998, bringing twenty-seven years of continuous legal practice to every case we handle. Admitted to the United States District Court for the Southern District of Texas, our firm is accustomed to the rigors of federal litigation—the same arena where major device manufacturers like Becton Dickinson, Allergan (AbbVie), and Mentor (Johnson & Johnson) are held accountable.
Our current role as lead counsel in high-profile institutional liability cases, such as Bermudez v. Pi Kappa Phi Fraternity, Inc. (Harris County, Texas), where we are seeking $10,000,000 in damages against thirteen defendants, demonstrates our capacity to pursue complex, multi-defendant litigation. We apply that same aggressive, investigative approach to New York breast mesh and scaffold cases. We don’t just look at what the surgeon did; we look at what the manufacturer hid. If you are a Spanish-speaking patient in New York, Lupe Peña provides direct, fluent communication and consultation, ensuring that no detail of your story is lost in translation. We are not just a law firm; we are yours and your family’s advocates in the fight for accountability.
Understanding the Devices: Mesh, ADM, and Scaffolds
Many patients in New York are surprised to learn that the “internal bra” or reinforcement used in their surgery was actually a derivative of cadaver skin or a synthetic knit originally designed for hernia repair. These products are broadly categorized into three types, yet they share a common thread: none of them were ever formally approved by the FDA specifically for use in breast surgery.
Acellular Dermal Matrix (ADM)
ADM is a biologic material, typically derived from human cadaver skin (allograft) or porcine/bovine tissue (xenograft), that has been processed to remove cells while leaving the extracellular matrix intact. Familiar brands used in New York hospitals include:
- AlloDerm / AlloDerm RTU (Allergan/AbbVie)
- FlexHD (MTF Biologics)
- Strattice (Allergan/AbbVie)
- AlloMax (Becton Dickinson/C.R. Bard)
The FDA issued a critical Safety Communication in March 2021, revealing that FlexHD and AlloMax showed significantly higher rates of explantation, reoperation, and infection compared to other ADMs or no ADM use at all.
Bioabsorbable and Resorbable Scaffolds
These are synthetic, dissolvable reinforcements meant to support the weight of an implant or natural tissue while the body creates its own scar tissue. The most prominent material used today is poly-4-hydroxybutyrate (P4HB).
- GalaFLEX / GalaFLEX Lite (Galatea Surgical/Becton Dickinson)
- Phasix Mesh (Becton Dickinson/C.R. Bard)
- DuraSorb (Integra LifeSciences)
The P4HB material is designed to hydrolyze (break down) over 18 to 24 months. However, many New York patients report that these scaffolds do not dissolve as advertised, leading to palpable ridges, chronic inflammation, and “red breast syndrome”—a condition where the breast remains chronically red and hot due to a non-infectious reaction to the device.
The Regulatory Failure: The 510(k) Loophole
A central question many New York survivors ask us is: “How was this allowed to be used if it wasn’t approved for the breast?” The answer lies in the FDA’s 510(k) clearance pathway (21 CFR Part 807 Subpart E). Unlike the rigorous Premarket Approval (PMA) process that requires human clinical trials to prove safety and effectiveness, the 510(k) pathway only requires a manufacturer to show that their device is “substantively equivalent” to a “predicate” device already on the market.
This has led to what we call “predicate creep.” For example, the manufacturers of GalaFLEX cited a surgical suture as one of their predicates. Across generations of clearances, devices evolved from simple sutures to complex meshes without ever being tested in the unique environment of human breast tissue. Because of the Supreme Court’s holding in Medtronic v. Lohr, 518 U.S. 470 (1996), these 510(k)-cleared devices are not shielded by the federal preemption that often protects higher-risk Class III devices. This means that in New York, we can pursue state-law claims for design defects, manufacturing defects, and failure to warn.
Crucial Diagnoses: BIA-ALCL and BIA-SCC
For women who received textured implants—most notably the Allergan BIOCELL line—the risks extend beyond simple mechanical failure. Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is a T-cell non-Hodgkin lymphoma that develops in the capsule surrounding the implant. It is not breast cancer; it is a cancer of the immune system.
Pathologically, BIA-ALCL is characterized as CD30-positive and ALK-negative. If you are experiencing late-onset seroma (fluid collection) or a mass appearing 7 to 10 years after your surgery, this must be investigated immediately.
Furthermore, in September 2022, the FDA issued a safety communication regarding BIA-SCC (Breast Implant-Associated Squamous Cell Carcinoma). Unlike ALCL, this epithelial tumor has been found in the capsules of both textured and smooth implants. For patients in the New York medical hub, these diagnoses require immediate surgical intervention and specialized oncological care. We are already tracking the Allergan BIOCELL MDL 2921 in the District of New Jersey, where the first bellwether trials are currently scheduled for October 19, 2026. If you have been diagnosed, your time to file is governed by New York’s specific legal statutes.
The Whistleblower: What the Manufacturers Knew
Our investigation into these devices is bolstered by the courage of whistleblowers like Dr. Hooman Noorchashm. A cardiothoracic surgeon and former Medical Director at Becton Dickinson (BD), Dr. Noorchashm was terminated in 2022 after raising alarms about the safety of GalaFLEX. His allegations are stunning: he asserts that BD knew about breast cancer recurrences in GalaFLEX clinical trials but failed to adequately report them to the FDA.
Furthermore, Dr. Noorchashm has highlighted the massive underreporting in the FDA’s MAUDE (Manufacturer and User Facility Device Experience) database. Patients in New York who believed their reconstruction was failing due to “bad luck” or “personal biology” may actually be victims of a product that carries an unacceptably high endotoxin load or a failure to resorb, resulting in a chronic foreign-body response. When you call us at 1-888-ATTY-911, we use this insider knowledge to challenge the “safety” narratives provided by defense counsel.
New York Legal Framework: Statutes and Deadlines
In New York, time is your most precious resource, but also your most dangerous adversary. The general statute of limitations for personal injury and product liability in New York is three years from the date of the injury (CPLR § 214). However, for many women, the injury isn’t apparent the moment the mesh is implanted.
New York’s “Discovery Rule” is notoriously complex. While some states allow the clock to start when you discover the link between the device and your injury, New York has historically been more restrictive, particularly in cases involving “toxic torts” or latent exposure. However, if your injury involves a malignancy like BIA-ALCL or BIA-SCC, or if there was fraudulent concealment by the manufacturer, different rules may apply.
Because the law is in constant flux and varies significantly between the Southern District of New York (Manhattan/Bronx) and the Eastern District of New York (Brooklyn/Queens/Long Island), you cannot afford to guess. We evaluate the specific venue of your surgery—whether it was at a high-volume cosmetic practice on the Upper East Side or an academic center in Stoney Brook—to determine the best jurisdictional path for your claim.
The Specter of Sepsis and Reconstruction Failure
For many of our clients, the primary injury isn’t cancer, but the catastrophic loss of their reconstruction. Complications we frequently see in New York cases include:
- Skin-flap necrosis: The death of the skin overlying the reconstruction.
- Explant surgery: The forced removal of the mesh and implant due to intractable infection.
- Sepsis: A systemic, life-threatening response to infection that can lead to organ failure or death.
- Chronic Pain: Intercostal neuralgia caused by the mesh edges irritating the chest wall.
The “3x Multiplication” of our strategy means we evaluate the legal context, our firm’s deep investigation into institutional negligence, and the direct impact on your life in New York. A generalist firm might see a “surgical complication.” We see a failure to warn about the known infection risks of FlexHD, or a design defect in P4HB scaffolds that fail to hydrolyze.
How to Protect Your Rights in New York
If you suspect your breast mesh or scaffold is causing you harm, we recommend taking these four steps immediately:
- Request Your Operative Reports: You have a legal right to your medical records. Specifically, look for the “Implant Log” or “Device Stickers.” These contain the Unique Device Identifier (UDI), lot numbers, and brand names we need to identify the manufacturer.
- Preserve the Evidence: If you undergo a revision or explant surgery, tell your surgeon and the hospital pathology department that you want the removed mesh or scaffold preserved. This is physical evidence. Do not let the hospital return it to the manufacturer for “evaluation”—it is your property.
- Document the Progression: Keep a journal of your symptoms. Photographs of “red breast syndrome” or wound dehiscence are powerful evidence of the physical toll the device has taken.
- Contact Attorney911: Call 1-888-ATTY-911. We offer a fee-free, no-obligation assessment of your case. Because we work on a contingency basis, you never pay us out of pocket. We only get paid if we recover compensation for you.
Frequently Asked Questions for New York Patients
Is surgical mesh actually approved for breast surgery?
No. The FDA has explicitly stated as recently as November 2023 that no surgical mesh products—including ADMs and scaffolds—have been cleared or approved for use in breast reconstruction or augmentation. Their use is considered “off-label.”
Can I sue the manufacturer if I live in New York but had surgery elsewhere?
Yes. Product liability cases are often filed in federal court or in the state where the manufacturer is headquartered. We handle multi-jurisdictional litigation and can determine the most advantageous venue for your specific case.
What if I don’t know the brand of mesh used in my body?
This is common. We can help you secure the necessary hospital records and track down the device identifiers through the hospital’s supply chain records.
Does Lupe Peña really handle the whole case in Spanish?
Yes. For our New York clients who are more comfortable speaking Spanish, Lupe Peña conducts consultations and maintains communication in Spanish, ensuring you have direct access to your attorney without needing an interpreter.
What is the “learned intermediary” defense?
Manufacturers often argue that they only had a duty to warn your surgeon, not you. However, when manufacturers engage in direct-to-consumer advertising or off-label promotion directly to surgeons (as alleged in the GalaFLEX litigation), that defense can be overcome.
Your Path Forward: Contact Attorney911 Today
The Manginello Law Firm, PLLC is dedicated to the principle that a woman’s body is not a testing ground for medical device manufacturers. If you are suffering in New York because of a defective acellular dermal matrix, a bioabsorbable scaffold, or a textured implant, you deserve a firm that understands the science as well as the law.
Our firm is recognized for excellence, including Ralph Manginello’s Avvo “Excellent” tier rating (8.2/10) and Martindale-Hubbell Preeminent status. We have hundreds of five-star reviews from clients who have trusted us during their most difficult moments. We bring that same level of commitment to every New York breast mesh survivor we represent.
Do not allow the statute of limitations to close the door on your right to compensation. Whether you are in Manhattan, Brooklyn, Albany, or Buffalo, we are ready to listen to your story. Call us today at 1-888-ATTY-911 or contact us through our website. Hablamos español. We fight for the compensation you need to cover revision surgeries, lost wages, and the pain you have endured. Let us be your voice against the medical device industry.
Attorney911: Aggressive Representation. Compassionate Support. No Fee Unless We Recover.
